encephalopathies, such as the Lennox-Gastaut syndrome.' The effects of non-convulsive status on cerebral metabolism are uncertain. In children with intractable seizure disorders, however, the incidence and degree of subsequent mental retardation is greater in those who have had one or more episode of non-convulsive status compared with those who have had no episodes.1 2 In addition, during these episodes, the children are very slow to react to any stimuli, are unable to concentrate, have no ability to learn, become disorientated and confused, and often lose speech. Episodes of nonconvulsive status may last from a few hours up to several months.3 For these reasons such episodes are regarded by many as a paediatric emergency requiring aggressive treatment.
While it is recognised that non-convulsive status may be drug resistant, in general intravenous benzodiazepines have been considered to be the drugs of choice for this complication. 2-4 Gastaut has gone as far as to say that all cases of absence status respond within a few minutes to intravenous benzodiazepines.5
We report here our experience with seven patients presenting in non-convulsive status treated with benzodiazepines.
Patients and methods
The patients reported here formed part of a group of 40 patients with intractable seizure disorders in whom testing of benzodiazepine sensitivity has been carried out. Nine out of the forty (23%) had an electroclinical diagnosis of the Lennox-Gastaut syndrome, and seven of these nine presented with at least one episode of non-convulsive status. These seven patients had testing of benzodiazepine sensitivity performed during the acute episodes of status and form the subject of this paper.
Details of the seven patients are shown in the Table. All patients were attending the paediatric epilepsy service at the Royal Hospital for Sick Children, Edinburgh. There were four boys and three girls. The mean age of presentation was 7 years (range 3-13 years). The aetiology in all cases was unknown, but in one patient it was presumed to be prenatal in origin as he showed dysmorphic features with microcephaly. The usual seizure type in most patients comprised drop attacks, complex absences, myoclonic jerks, and tonic seizures. All patients had presented with increased frequency in their usual seizures, followed by onset of unresponsiveness, drooling, and prolonged absences, in some cases associated with loss of speech and ataxia.
In all the patients the electroencephalogram (EEG) showed continuous or almost continuous slow spike or polyspike and wave of varying degrees of symmetry and synchrony. The duration of status as determined by history ranged from two days to five weeks (mean 10 days).
All patients were given intravenous benzodiazepines during continuous EEG monitoring. Five patients were given diazepam in a dose of 0-2-0-3 mg/kg, one was given clonazepam in a dose of 0-02 mg/kg, and one was given both clonazepam and diazepam. In addition, other anticonvulsants are known to interact directly at the benzodiazepine receptor or to have other effects on GABA mediated inhibition. As well as the conformational and interactional changes that may occur in benzodiazepine receptors, it is also known that changes in receptor numbers may occur with chronic treatment, and thus both down regulation and up regulation of receptors have been described. 9 Five of the seven patients in this group had previously been on oral treatment with benzodiazepines and thus these mechanisms may explain their subsequent lack of response. Two of the patients, however, had no previous exposure to them and clearly down regulation of receptors could not explain the lack of response in these patients. It does seem, however, that the chronicity of the seizure disorder, together with the need for many different anticonvulsants taken over long periods, seem to make negative or paradoxical responses more likely.
The benzodiazepines are the most effective treatment for convulsive status epilepticus available and from this small series we would not suggest that they should be avoided in the treatment of nonconvulsive status. These results illustrate, however, that many patients with non-convulsive status will not respond to them in the acute stage. We would emphasise the importance of continuous EEG monitoring during the treatment of these patients to assess the effects and watch for unusual or paradoxical responses that are more common in this group of patients. If Although there is increasing concern about the possible brain damage caused by recurrent bouts of non-convulsive status, treatment of these states remain frustratingly difficult with the current anticonvulsants at our disposal.
